IV Drug Usage, Unsafe Sex
Conditions
Brief summary
This study will evaluate the implementation of a PrEP program for youth aged 13-24 in Phoenix, AZ. Numbers of youth who initiate PrEP, how long they continue with PrEP, and the barriers for youth who are trying to initiate and continue taking PrEP will be examined.
Detailed description
This observational study will describe the barriers encountered and the benefits found as youth engage in a PrEP program, the Phoenix PrEP Access Project and as they participate in PrEP provided through standard medical care. This study does not investigate the safety, efficacy or other medical benefits of PrEP, but looks at the issues surrounding youth who are trying to access PrEP.
Interventions
None listed
Sponsors
Phoenix Children's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
13 Years to 24 Years
Healthy volunteers
No
Inclusion criteria
* sexually active youth aged 13 through 24, * at risk for contracting HIV, * Negative for HIV as indicated by Negative Elisa and Western Blot (WB) or Negative 4th Generation test, * weight greater than 35kg, * offered PrEP to reduce the risk of contracting HIV.
Exclusion criteria
* Unknown or Positive HIV status, * Renal Impairment as indicated by elevated BUN or Creatinine, abnormal urinalysis, * Active infection with Hepatitis B Virus, * Taking other medications containing Emtricitabine, Tenofovir or tenofovir alafenamide(TAF) such as Atripla, Complera, Emtriva, Genvoya, Odefsey, Stribild, and Viread taking drugs containing lamivudine, * taking Hepsera, * clinical symptoms consistent with acute viral infection within the past month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PrEP Uptake | 3 years | Uptake of PrEP offered to youth presenting for PrEP ages 13-24 |
Countries
United States
Outcome results
None listed